Amyloid positron emission tomography (PET) imaging is being investigated as a screening tool to identify amyloid-positive patients as an enrichment strategy for Alzheimer disease (AD) clinical trial enrollment. In a multicenter, phase 1b trial, patients meeting clinical criteria for prodromal or mild...
Results With regard to outcomes, amyloid PET could be of use in the context of an amyloid-lowering drug in a clinical trial. Imaging might also be of use in assessing drugs that inhibit the formation of fibrillar forms of Abeta. However, amyloid PET is of course unlikely to be useful in...
Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials Experience in a Phase 1b Clinical Trial Amyloid positron emission tomography (PET) imaging Chen,Tianle,Klein,... - 《Alzheimer Disease & Associated Disorders》 被引量: 21发表: 2016年 加载更多来源...
Amyloid-PET quantification supports the identification of CN individuals at risk of functional decline. Trial registration The AMYPAD PNHS is registered at www.clinicaltrialsregister.eu with the EudraCT Number: 2018-002277-22.Introduction Alzheimer’s disease (AD) is assumed to begin with an abnormal...
CDR: Clinical Dementia Rating scale, ApoE: apolipoprotein E, Aβ: amyloid beta, amyloid PET: amyloid positron emission tomography, LP: lumbar puncture, SCD: subjective cognitive decline. An individual could meet more than one exclusion criterion Full size image Determination of amyloid status Amyloid...
AD biomarkers will have a central role in future clinical trials to enable early diagnosis, and Aβ biomarkers (CSF Aβ42 and amyloid PET) may be essential to allow for testing a drug on patients with evidence of brain Aβ pathology. Pharmacodynamic Aβ and amyloid precursor protein ...
R. et al. Biochemically-defined pools of amyloid-β in sporadic Alzheimer's disease: correlation with amyloid PET. Brain 140, 1486–1498 (2017). Article PubMed Google Scholar Bush, A. I. et al. The amyloid precursor protein of Alzheimer's disease is released by human platelets. J. ...
The effect of bapineuzumab treatment on cortical fibrillar Ab load as measured by PiB–PET was evaluated in a double-blind, placebo-controlled clinical trial over 78 weeks of treatment. This study showed a reduction in cortical PiB retention with treatment in several cortical brain regions, both ...
Kobylecki C, Langheinrich T, Hinz R, Vardy ER, Brown G, Martino ME, et al. 18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease. J Nucl Med. 2015;56(3):386–91. CASPubMedGoogle Scholar Hatashita S, Yamasaki H, Suzuki Y, Tanaka K, Wakebe D, Hayakawa ...
High continuity of care (COC) is associated with better clinical outcomes among older adults. The impact of amyloid-β PET scan on COC among adults with mild cognitive impairment (MCI) or dementia of uncertain etiology is unknown. We linked data from the